Citations (141)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (11)
Aishwarya Jala, Srikanth Ponneganti, Devi Swetha Vishnubhatla, Gayathri Bhuvanam, Prithvi Raju Mekala, Bincy Varghese, Pullapanthula Radhakrishnanand, Ramu Adela, Upadhyayula Suryanarayana Murty & Roshan M. Borkar. (2021) Transporter-mediated drug–drug interactions: advancement in models, analytical tools, and regulatory perspective. Drug Metabolism Reviews 53:3, pages 285-320.
Read now
Read now
Sumathy Mathialagan, Chester Costales, Laurie Tylaska, Emi Kimoto, Anna Vildhede, Jillian Johnson, Nathaniel Johnson, Takami Sarashina, Kenta Hashizume, Caleb D. Isringhausen, Lydia M. M. Vermeer, Andrea R. Wolff & A. David Rodrigues. (2018) In vitro studies with two human organic anion transporters: OAT2 and OAT7. Xenobiotica 48:10, pages 1037-1049.
Read now
Read now
Melinda J. Reese, Gary D. Bowers, Joan E. Humphreys, Elizabeth P. Gould, Susan L. Ford, Lindsey O. Webster & Joseph W. Polli. (2016) Drug interaction profile of the HIV integrase inhibitor cabotegravir: assessment from in vitro studies and a clinical investigation with midazolam. Xenobiotica 46:5, pages 445-456.
Read now
Read now
Yukari Umeyama, Yasushi Fujioka & Teruaki Okuda. (2014) Clarification of P-glycoprotein inhibition-related drug–drug interaction risks based on a literature search of the clinical information. Xenobiotica 44:12, pages 1135-1144.
Read now
Read now
Jef Stappaerts, Sarinj Fattah, Pieter Annaert & Patrick Augustijns. (2014) Hepatobiliary and intestinal elimination of darunavir in an integrated preclinical rat model. Xenobiotica 44:6, pages 489-497.
Read now
Read now
William J. Chiou, Sonia M. de Morais, Ryota Kikuchi, Richard L. Voorman, Xiaofeng Li & Daniel A. J. Bow. (2014) In vitro OATP1B1 and OATP1B3 inhibition is associated with observations of benign clinical unconjugated hyperbilirubinemia. Xenobiotica 44:3, pages 276-282.
Read now
Read now
Roberto Lozano, Nieves Domeque & Alberto-Fermin Apesteguia. (2013) Atazanavir–bilirubin interaction: a pharmacokinetic–pharmacodynamic model. Clinical Pharmacology: Advances and Applications 5, pages 153-159.
Read now
Read now
Nicolas Picard, Laure Levoir, Fabien Lamoureux, Sook Wah Yee, Kathleen M. Giacomini & Pierre Marquet. (2011) Interaction of sirolimus and everolimus with hepatic and intestinal organic anion-transporting polypeptide transporters. Xenobiotica 41:9, pages 752-757.
Read now
Read now
Grant T. Generaux, Fiorenza M. Bonomo, Marta Johnson & Kelly M. Mahar Doan. (2011) Impact of SLCO1B1 (OATP1B1) and ABCG2 (BCRP) genetic polymorphisms and inhibition on LDL-C lowering and myopathy of statins. Xenobiotica 41:8, pages 639-651.
Read now
Read now
. (2010) Invited Speakers. Drug Metabolism Reviews 42:sup1, pages 1-323.
Read now
Read now
Articles from other publishers (130)
Catia Marzolini, Matthias Cavassini, Dominique L. Braun, Anna Hachfeld, Enos Bernasconi, Alexandra Calmy, Patrick Schmid, Manuel Battegay & Luigia Elzi. (2023) Effect of SLCO1B1 c.521T>C polymorphism on the lipid response to statins in people living with HIV on a boosted protease inhibitor‐containing regimen. British Journal of Clinical Pharmacology 89:9, pages 2739-2746.
Crossref
Crossref
Éva Bakos, Csilla Temesszentandrási-Ambrus, Csilla Özvegy-Laczka, Zsuzsanna Gáborik, Balázs Sarkadi & Ágnes Telbisz. (2023) Interactions of the Anti-SARS-CoV-2 Agents Molnupiravir and Nirmatrelvir/Paxlovid with Human Drug Transporters. International Journal of Molecular Sciences 24:14, pages 11237.
Crossref
Crossref
Ying Zhang, Mark Johnson, Samit Joshi, Parto Yazdani, Joyce Zhan, Bo Wen, Veronica Bainbridge, Martin Gartland & Max Lataillade. (2023) Open‐label, drug–drug interaction study between the HIV‐1 maturation inhibitor GSK3640254 and a metabolic probe cocktail in healthy participants. British Journal of Clinical Pharmacology 89:7, pages 2236-2245.
Crossref
Crossref
Nancy H.C. Loos, Jos H. Beijnen & Alfred H. Schinkel. (2023) The inhibitory and inducing effects of ritonavir on hepatic and intestinal CYP3A and other drug-handling proteins. Biomedicine & Pharmacotherapy 162, pages 114636.
Crossref
Crossref
Cheng Ji. (2023) Molecular Factors and Pathways of Hepatotoxicity Associated with HIV/SARS-CoV-2 Protease Inhibitors. International Journal of Molecular Sciences 24:9, pages 7938.
Crossref
Crossref
Robert Elsby, Hannah Coghlan, Jacob Edgerton, David Hodgson, Samuel Outteridge & Hayley Atkinson. (2023)
Mechanistic in vitro studies indicate that the clinical drug–drug interactions between protease inhibitors and rosuvastatin are driven by inhibition of intestinal
BCRP
and hepatic
OATP1B1
with minimal contribution from
OATP1B3
,
NTCP
and
OAT3
. Pharmacology Research & Perspectives 11:2.
Crossref
Crossref
Csilla Özvegy-Laczka, Orsolya Ungvári & Éva Bakos. (2023) Fluorescence-based methods for studying activity and drug-drug interactions of hepatic solute carrier and ATP binding cassette proteins involved in ADME-Tox. Biochemical Pharmacology 209, pages 115448.
Crossref
Crossref
Beatriz Sanchez de Blas, Alvaro G. Temprano, Jose J. G. Marin & Marta R. Romero. (2023) Monitoring the hepatobiliary function using image techniques and labeled cholephilic compounds. Exploration of Digestive Diseases, pages 18-33.
Crossref
Crossref
Hongye Han, Takeshi Akiyoshi, Tokio Morita, Hiroki Kataoka, Kazuhiro Katayama, Kodai Yajima, Ayuko Imaoka & Hisakazu Ohtani. (2022) Comparison of the transport kinetics of fexofenadine and its pH dependency among OATP1A2 genetic variants. Drug Metabolism and Pharmacokinetics 47, pages 100470.
Crossref
Crossref
Sonu Abraham, Anju Nohria, Tomas G. Neilan, Aarti Asnani, Anu Mariam Saji, Jui Shah, Tara Lech, Jason Grossman, George M. Abraham, Daniel P. McQuillen, David T. Martin, Paul E. Sax, Sourbha S. Dani & Sarju Ganatra. (2022) Cardiovascular Drug Interactions With Nirmatrelvir/Ritonavir in Patients With COVID-19. Journal of the American College of Cardiology 80:20, pages 1912-1924.
Crossref
Crossref
Nicolas Cottura, Hannah Kinvig, Sandra Grañana‐Castillo, Adam Wood & Marco Siccardi. (2022) Drug–Drug Interactions in People Living With HIV at Risk of Hepatic and Renal Impairment: Current Status and Future Perspectives. The Journal of Clinical Pharmacology 62:7, pages 835-846.
Crossref
Crossref
Nicolás R. Robles, Francesco Fici, Julian Valladares & Guido Grassi. (2021) Antiretroviral Treatment and Antihypertensive Therapy. Current Pharmaceutical Design 27:40, pages 4116-4124.
Crossref
Crossref
Taleah Farasyn, Sonia Pahwa, Chao Xu & Wei Yue. (2021) Pre-incubation with OATP1B1 and OATP1B3 inhibitors potentiates inhibitory effects in physiologically relevant sandwich-cultured primary human hepatocytes. European Journal of Pharmaceutical Sciences 165, pages 105951.
Crossref
Crossref
Csilla Ambrus, Éva Bakos, Balázs Sarkadi, Csilla Özvegy-Laczka & Ágnes Telbisz. (2021) Interactions of anti-COVID-19 drug candidates with hepatic transporters may cause liver toxicity and affect pharmacokinetics. Scientific Reports 11:1.
Crossref
Crossref
Perrine Courlet, Monia Guidi, Susana Alves Saldanha, Felix Stader, Anna Traytel, Matthias Cavassini, Marcel Stoeckle, Thierry Buclin, Catia Marzolini, Laurent A. Decosterd & Chantal Csajka. (2020) Pharmacokinetic/Pharmacodynamic Modelling to Describe the Cholesterol Lowering Effect of Rosuvastatin in People Living with HIV. Clinical Pharmacokinetics 60:3, pages 379-390.
Crossref
Crossref
Ágnes Telbisz, Csilla Ambrus, Orsolya Mózner, Edit Szabó, György Várady, Éva Bakos, Balázs Sarkadi & Csilla Özvegy-Laczka. (2021) Interactions of Potential Anti-COVID-19 Compounds with Multispecific ABC and OATP Drug Transporters. Pharmaceutics 13:1, pages 81.
Crossref
Crossref
Julian C. Gilmore, Lena Serghides & Reina Bendayan. (2021) Differential effects of antiretroviral drug toxicity in male versus female children who are HIV-exposed but uninfected. AIDS 35:1, pages 1-14.
Crossref
Crossref
Sana-Kay Whyte-Allman & Reina Bendayan. (2020) HIV-1 Sanctuary Sites—the Role of Membrane-Associated Drug Transporters and Drug Metabolic Enzymes. The AAPS Journal 22:5.
Crossref
Crossref
Vineet Kumar, Cindy Yanfei Li, Kazuya Ishida, Emese Kis, Zsuzsanna Gáborik & Jashvant D. Unadkat. (2020) Pitfalls in Predicting Hepatobiliary Drug Transport Using Human Sandwich-Cultured Hepatocytes. The AAPS Journal 22:5.
Crossref
Crossref
Perrine Courlet, Laurent A. Decosterd, Susana Alves Saldanha, Matthias Cavassini, Felix Stader, Marcel Stoeckle, Thierry Buclin, Catia Marzolini, Chantal Csajka & Monia Guidi. (2020) Influence of Drug–Drug Interactions on the Pharmacokinetics of Atorvastatin and Its Major Active Metabolite ortho-OH-Atorvastatin in Aging People Living with HIV. Clinical Pharmacokinetics 59:8, pages 1037-1048.
Crossref
Crossref
Felix Stader, Laurent Decosterd, Marcel Stoeckle, Matthias Cavassini, Manuel Battegay, Susana Alves Saldanha, Catia Marzolini & Perrine Courlet. (2020) Aging does not impact drug--drug interaction magnitudes with antiretrovirals. AIDS 34:6, pages 949-952.
Crossref
Crossref
Yoshitane Nozaki & Saki Izumi. (2020) Recent advances in preclinical in vitro approaches towards quantitative prediction of hepatic clearance and drug-drug interactions involving organic anion transporting polypeptide (OATP) 1B transporters. Drug Metabolism and Pharmacokinetics 35:1, pages 56-70.
Crossref
Crossref
Matthew P Kosloski, Rajneet Oberoi, Stanley Wang, Rolando M Viani, Armen Asatryan, Beibei Hu, Bifeng Ding, Xin Qi, Elaine J Kim, Federico Mensa, Jens Kort & Wei Liu. (2020) Drug-Drug Interactions of Glecaprevir and Pibrentasvir Coadministered With Human Immunodeficiency Virus Antiretrovirals. The Journal of Infectious Diseases 221:2, pages 223-231.
Crossref
Crossref
Hiroyuki Murata, Soichiro Ito, Hiroyuki Kusuhara, Yukihiro Nomura & Toshio Taniguchi. (2019) Proposal of a Parameter for OATP1B1 Inhibition Screening at the Early Drug Discovery Stage. Journal of Pharmaceutical Sciences 108:12, pages 3898-3902.
Crossref
Crossref
E.M. Hodel, C. Marzolini, C. Waitt & N. Rakhmanina. (2019) Pharmacokinetics, Placental and Breast Milk Transfer of Antiretroviral Drugs in Pregnant and Lactating Women Living with HIV. Current Pharmaceutical Design 25:5, pages 556-576.
Crossref
Crossref
Sauzanne G. Khalilieh, Ka Lai Yee, Rosa I. Sanchez, Li Fan, Matt S. Anderson, Monali Sura, Tine Laethem, Scott Rasmussen, Luc van Bortel, Griet van Lancker & Marian Iwamoto. (2019) Doravirine and the Potential for CYP3A-Mediated Drug-Drug Interactions. Antimicrobial Agents and Chemotherapy 63:5.
Crossref
Crossref
Lyrialle W. Han, Chunying Gao, Yuchen Zhang, Joanne Wang & Qingcheng Mao. (2019) Transport of Bupropion and its Metabolites by the Model CHO and HEK293 Cell Lines. Drug Metabolism Letters 13:1, pages 25-36.
Crossref
Crossref
Hwa-Ping Feng, Luzelena Caro, Christine Fandozzi, Xiaoyan Chu, Zifang Guo, Jennifer Talaty, Deborah Panebianco, Katherine Dunnington, Lihong Du, William D. Hanley, Iain P. Fraser, Anna Mitselos, Jean-Francois Denef, Inge De Lepeleire, Jan N. de Hoon, Corinne Vandermeulen, William L. Marshall, Patricia Jumes, Xiaobi Huang, Monika Martinho, Robert Valesky, Joan R. Butterton, Marian Iwamoto & Wendy W. Yeh. (2019) Pharmacokinetic Interactions between the Hepatitis C Virus Inhibitors Elbasvir and Grazoprevir and HIV Protease Inhibitors Ritonavir, Atazanavir, Lopinavir, and Darunavir in Healthy Volunteers. Antimicrobial Agents and Chemotherapy 63:4.
Crossref
Crossref
Yaru Xue, Chenhui Ma, Imad Hanna & Guoyu Pan. 2019. Drug Transporters in Drug Disposition, Effects and Toxicity. Drug Transporters in Drug Disposition, Effects and Toxicity
361
405
.
Anima M. Schäfer, Thomas Bock & Henriette E. Meyer zu Schwabedissen. (2018) Establishment and Validation of Competitive Counterflow as a Method To Detect Substrates of the Organic Anion Transporting Polypeptide 2B1. Molecular Pharmaceutics 15:12, pages 5501-5513.
Crossref
Crossref
Annett Kunze, Emmanuel Njumbe Ediage, Lieve Dillen, Mario Monshouwer & Jan Snoeys. (2018) Clinical Investigation of Coproporphyrins as Sensitive Biomarkers to Predict Mild to Strong OATP1B-Mediated Drug–Drug Interactions. Clinical Pharmacokinetics 57:12, pages 1559-1570.
Crossref
Crossref
Pablo Torres-Vergara, Carlos Escudero & Jeffrey Penny. (2018) Drug Transport at the Brain and Endothelial Dysfunction in Preeclampsia: Implications and Perspectives. Frontiers in Physiology 9.
Crossref
Crossref
Tony K. L. Kiang. (2018) Clinical Pharmacokinetics and Drug–Drug Interactions of Elbasvir/Grazoprevir. European Journal of Drug Metabolism and Pharmacokinetics 43:5, pages 509-531.
Crossref
Crossref
Shelby Barnett, Kayode Ogungbenro, Karelle Ménochet, Hong Shen, Yurong Lai, W. Griffith Humphreys & Aleksandra Galetin. (2018) Gaining Mechanistic Insight Into Coproporphyrin I as Endogenous Biomarker for OATP1B-Mediated Drug-Drug Interactions Using Population Pharmacokinetic Modeling and Simulation. Clinical Pharmacology & Therapeutics 104:3, pages 564-574.
Crossref
Crossref
Yu Chen, Lin Chen, Hong Zhang, Shibo Huang, Yuqing Xiong & Chunhua Xia. (2018) Interaction of Sulfonylureas with Liver Uptake Transporters OATP1B1 and OATP1B3. Basic & Clinical Pharmacology & Toxicology 123:2, pages 147-154.
Crossref
Crossref
Nico Holmstock, Marlies Oorts, Jan Snoeys & Pieter Annaert. (2018) MRP2 Inhibition by HIV Protease Inhibitors in Rat and Human Hepatocytes: A Quantitative Confocal Microscopy Study. Drug Metabolism and Disposition 46:5, pages 697-703.
Crossref
Crossref
Maria Alvarellos, Chantal Guillemette, Russ B. Altman & Teri E. Klein. (2018) PharmGKB summary. Pharmacogenetics and Genomics 28:5, pages 127-137.
Crossref
Crossref
Khondoker Alam, Alexandra Crowe, Xueying Wang, Pengyue Zhang, Kai Ding, Lang Li & Wei Yue. (2018) Regulation of Organic Anion Transporting Polypeptides (OATP) 1B1- and OATP1B3-Mediated Transport: An Updated Review in the Context of OATP-Mediated Drug-Drug Interactions. International Journal of Molecular Sciences 19:3, pages 855.
Crossref
Crossref
Izabel Patik, Virág Székely, Orsolya Német, Áron Szepesi, Nóra Kucsma, György Várady, Gergely Szakács, Éva Bakos & Csilla Özvegy-Laczka. (2018) Identification of novel cell-impermeant fluorescent substrates for testing the function and drug interaction of Organic Anion-Transporting Polypeptides, OATP1B1/1B3 and 2B1. Scientific Reports 8:1.
Crossref
Crossref
Darren Michael Moss, Marco Siccardi & Catia Marzolini. 2018. Drug Interactions in Infectious Diseases: Mechanisms and Models of Drug Interactions. Drug Interactions in Infectious Diseases: Mechanisms and Models of Drug Interactions
49
85
.
Khondoker Alam, Taleah Farasyn, Alexandra Crowe, Kai Ding & Wei Yue. (2017) Treatment with proteasome inhibitor bortezomib decreases organic anion transporting polypeptide (OATP) 1B3-mediated transport in a substrate-dependent manner. PLOS ONE 12:11, pages e0186924.
Crossref
Crossref
Kenneth W. Dunn & Jennifer C. Ryan. (2017) Using quantitative intravital multiphoton microscopy to dissect hepatic transport in rats. Methods 128, pages 40-51.
Crossref
Crossref
Jingjing Yu, Zhu Zhou, Jessica Tay-Sontheimer, René H. Levy & Isabelle Ragueneau-Majlessi. (2017) Intestinal Drug Interactions Mediated by OATPs: A Systematic Review of Preclinical and Clinical Findings. Journal of Pharmaceutical Sciences 106:9, pages 2312-2325.
Crossref
Crossref
Ayman F. El‐Kattan. 2017. Oral Bioavailability Assessment. Oral Bioavailability Assessment
269
307
.
Ayman F. El‐Kattan. 2017. Oral Bioavailability Assessment. Oral Bioavailability Assessment
77
138
.
Owain Roberts, Saye Khoo, Andrew Owen & Marco Siccardi. (2017)
Interaction of Rifampin and Darunavir-Ritonavir or Darunavir-Cobicistat
In Vitro
. Antimicrobial Agents and Chemotherapy 61:5.
Crossref
Crossref
David Metsu, Patrick Seraissol, Pierre Delobel, Christel Cinq-Frais, Lise Cuzin, Jacques Izopet, Etienne Chatelut & Peggy Gandia. (2017) Is the unbound concentration of atazanavir of interest in therapeutic drug monitoring?. Fundamental & Clinical Pharmacology 31:2, pages 245-253.
Crossref
Crossref
Taku Kobayashi, Takahiro Koizumi, Masaki Kobayashi, Jiro Ogura, Yuichi Horiuchi, Yuki Kimura, Ayuko Kondo, Ayako Furugen, Katsuya Narumi, Natsuko Takahashi & Ken Iseki. (2017) Insulin stimulates transport of organic anion compounds mediated by organic anion transporting polypeptide 2B1 in the human intestinal cell line Caco-2. Drug Metabolism and Pharmacokinetics 32:2, pages 157-163.
Crossref
Crossref
Andrew J. Chetwynd, Amanda Samarawickrama, Jaime H. Vera, Stephen A. Bremner, Alaa Abdul-Sada, Yvonne Gilleece, Stephen G. Holt & Elizabeth M. Hill. (2017) Nanoflow-Nanospray Mass Spectrometry Metabolomics Reveals Disruption of the Urinary Metabolite Profiles of HIV-Positive Patients on Combination Antiretroviral Therapy. JAIDS Journal of Acquired Immune Deficiency Syndromes 74:2, pages e45-e53.
Crossref
Crossref
Yan Dai, Bing-Liang Ma, Min Zheng, Rong Shi, Yuan-Yuan Li, Tian-Ming Wang & Yue-Ming Ma. (2017) Identification of drug transporters involved in the uptake and efflux of rhein in hepatocytes. RSC Advances 7:25, pages 15236-15245.
Crossref
Crossref
Takao Yamazaki, Amit Desai, David Han, Kota Kato, Donna Kowalski, Shahzad Akhtar, Christopher Lademacher, Laura Kovanda & Robert Townsend. (2017) Pharmacokinetic Interaction Between Isavuconazole and a Fixed-Dose Combination of Lopinavir 400 mg/Ritonavir 100 mg in Healthy Subjects. Clinical Pharmacology in Drug Development 6:1, pages 93-101.
Crossref
Crossref
Ismael Zamora & Susanne Winiwarter. (2016) Modeling Organic Anion-Transporting Polypeptide 1B1 Inhibition to Elucidate Interaction Risks in Early Drug Design. Journal of Pharmaceutical Sciences 105:10, pages 3214-3220.
Crossref
Crossref
Masanori Nakakariya, Akihiko Goto & Nobuyuki Amano. (2016) Appropriate risk criteria for OATP inhibition at the drug discovery stage based on the clinical relevancy between OATP inhibitors and drug-induced adverse effect. Drug Metabolism and Pharmacokinetics 31:5, pages 333-339.
Crossref
Crossref
N Marsousi, CF Samer, P Fontana, JL Reny, S Rudaz, JA Desmeules & Y Daali. (2016) Coadministration of ticagrelor and ritonavir: Toward prospective dose adjustment to maintain an optimal platelet inhibition using the PBPK approach. Clinical Pharmacology & Therapeutics 100:3, pages 295-304.
Crossref
Crossref
Camille Alam, Sana-Kay Whyte-Allman, Amila Omeragic & Reina Bendayan. (2016) Role and modulation of drug transporters in HIV-1 therapy. Advanced Drug Delivery Reviews 103, pages 121-143.
Crossref
Crossref
Laura Dickinson, Alan Winston, Marta Boffito, Saye Khoo, David Back & Marco Siccardi. (2016) Simulation of the impact of rifampicin on once-daily darunavir/ritonavir pharmacokinetics and dose adjustment strategies: a population pharmacokinetic approach. Journal of Antimicrobial Chemotherapy 71:4, pages 1041-1045.
Crossref
Crossref
Angela Colbers, Rick Greupink, Carlijn Litjens, David Burger & Frans G. M. Russel. (2015) Physiologically Based Modelling of Darunavir/Ritonavir Pharmacokinetics During Pregnancy. Clinical Pharmacokinetics 55:3, pages 381-396.
Crossref
Crossref
Saki Izumi, Yoshitane Nozaki, Takafumi Komori, Osamu Takenaka, Kazuya Maeda, Hiroyuki Kusuhara & Yuichi Sugiyama. (2016) Investigation of Fluorescein Derivatives as Substrates of Organic Anion Transporting Polypeptide (OATP) 1B1 To Develop Sensitive Fluorescence-Based OATP1B1 Inhibition Assays. Molecular Pharmaceutics 13:2, pages 438-448.
Crossref
Crossref
Magnus Ölander, Jacek R. Wiśniewski, Pär Matsson, Patrik Lundquist & Per Artursson. (2016) The Proteome of Filter-Grown Caco-2 Cells With a Focus on Proteins Involved in Drug Disposition. Journal of Pharmaceutical Sciences 105:2, pages 817-827.
Crossref
Crossref
Tom De Bruyn, Bruno Stieger, Patrick F. Augustijns & Pieter P. Annaert. (2016) Clearance Prediction of HIV Protease Inhibitors in Man: Role of Hepatic Uptake. Journal of Pharmaceutical Sciences 105:2, pages 854-863.
Crossref
Crossref
Stefanie Hennig, Suhashni Naiker, Tarylee Reddy, Deirdre Egan, Tracy Kellerman, Lubbe Wiesner, Andrew Owen, Helen McIlleron & Alexander Pym. (2016)
Effect of
SLCO1B1
Polymorphisms on Rifabutin Pharmacokinetics in African HIV-Infected Patients with Tuberculosis
. Antimicrobial Agents and Chemotherapy 60:1, pages 617-620.
Crossref
Crossref
. 2016. Molecular Microbiology. Molecular Microbiology
613
633
.
Marie Brännström, Pär Nordell, Britta Bonn, Andrew Davis, Anna-Pia Palmgren, Constanze Hilgendorf, Katarina Rubin & Ken Grime. (2015) Montelukast Disposition: No Indication of Transporter-Mediated Uptake in OATP2B1 and OATP1B1 Expressing HEK293 Cells. Pharmaceutics 7:4, pages 554-564.
Crossref
Crossref
Minlu Hu, Sravan Kumar Patel, Tian Zhou & Lisa C. Rohan. (2015) Drug transporters in tissues and cells relevant to sexual transmission of HIV: Implications for drug delivery. Journal of Controlled Release 219, pages 681-696.
Crossref
Crossref
Haichuan Duan, Tao Hu, Robert S. Foti, Yongmei Pan, Peter W. Swaan & Joanne Wang. (2015) Potent and Selective Inhibition of Plasma Membrane Monoamine Transporter by HIV Protease Inhibitors. Drug Metabolism and Disposition 43:11, pages 1773-1780.
Crossref
Crossref
Xiuli Li, Kan Zhong, Zitao Guo, Dafang Zhong & Xiaoyan Chen. (2015) Fasiglifam (TAK-875) Inhibits Hepatobiliary Transporters: A Possible Factor Contributing to Fasiglifam-Induced Liver Injury. Drug Metabolism and Disposition 43:11, pages 1751-1759.
Crossref
Crossref
Annett Kunze, Birk Poller, Jörg Huwyler & Gian Camenisch. (2015) Application of the extended clearance concept classification system (ECCCS) to predict the victim drug-drug interaction potential of statins. Drug Metabolism and Personalized Therapy 30:3, pages 175-188.
Crossref
Crossref
Thomas Ebner, Naoki Ishiguro & Mitchell E. Taub. (2015) The Use of Transporter Probe Drug Cocktails for the Assessment of Transporter-Based Drug–Drug Interactions in a Clinical Setting—Proposal of a Four Component Transporter Cocktail. Journal of Pharmaceutical Sciences 104:9, pages 3220-3228.
Crossref
Crossref
Christian Manzardo, Montserrat Tuset, Jose M. Miró & Jose M. Gatell. (2015) Interacciones graves o potencialmente letales entre antirretrovirales y otros medicamentos. Enfermedades Infecciosas y Microbiología Clínica 33:7, pages e15-e30.
Crossref
Crossref
Heather Sevinsky, Xiaolu Tao, Reena Wang, Palanikumar Ravindran, Karen Sims, Xiaohui Xu, Navin Jariwala & Richard Bertz. (2014) A Randomized Trial in Healthy Subjects to Assess the Bioequivalence of an Atazanavir/Cobicistat Fixed-Dose Combination Tablet versus Administration as Separate Agents. Antiviral Therapy 20:5, pages 493-500.
Crossref
Crossref
Janneke Keemink, Patrick Augustijns & Pieter Annaert. (2015) Unbound Ritonavir Concentrations in Rat and Human Hepatocytes. Journal of Pharmaceutical Sciences 104:7, pages 2378-2387.
Crossref
Crossref
Karolin Hijazi, Anna M. Cuppone, Kieron Smith, Maria A. Stincarelli, Julia Ekeruche-Makinde, Giulia De Falco, Georgina L. Hold, Robin Shattock, Charles G. Kelly, Gianni Pozzi & Francesco Iannelli. (2015) Expression of Genes for Drug Transporters in the Human Female Genital Tract and Modulatory Effect of Antiretroviral Drugs. PLOS ONE 10:6, pages e0131405.
Crossref
Crossref
Robert Gharavi, William Hedrich, Hongbing Wang & Hazem E. Hassan. (2015) Transporter-Mediated Disposition of Opioids: Implications for Clinical Drug Interactions. Pharmaceutical Research.
Crossref
Crossref
Barbara J. Brennan, Agnès Poirier, Sebastian Moreira, Peter N. Morcos, Petra Goelzer, Renée Portmann, Jiney Asthappan, Christoph Funk & Patrick F. Smith. (2014) Characterization of the Transmembrane Transport and Absolute Bioavailability of the HCV Protease Inhibitor Danoprevir. Clinical Pharmacokinetics 54:5, pages 537-549.
Crossref
Crossref
David W. Haas & Philip E. Tarr. (2015) Perspectives on pharmacogenomics of antiretroviral medications and HIV-associated comorbidities. Current Opinion in HIV and AIDS 10:2, pages 116-122.
Crossref
Crossref
STEFAN BRENNER, JULIANE RIHA, BENEDIKT GIESSRIGL, THERESIA THALHAMMER, MICHAEL GRUSCH, GEORG KRUPITZA, BRUNO STIEGER & WALTER JÄGER. (2015) The effect of organic anion-transporting polypeptides 1B1, 1B3 and 2B1 on the antitumor activity of flavopiridol in breast cancer cells. International Journal of Oncology 46:1, pages 324-332.
Crossref
Crossref
Carlos D. Malvestutto, Qing Ma, Gene D. Morse, James A. Underberg & Judith A. Aberg. (2014) Lack of Pharmacokinetic Interactions Between Pitavastatin and Efavirenz or Darunavir/Ritonavir. JAIDS Journal of Acquired Immune Deficiency Syndromes 67:4, pages 390-396.
Crossref
Crossref
Ar Kar Aung, David W Haas, Todd Hulgan & Elizabeth J Phillips. (2014) Pharmacogenomics of antimicrobial agents. Pharmacogenomics 15:15, pages 1903-1930.
Crossref
Crossref
Rucha S. Sane, Gerhard G. Steinmann, Qihong Huang, Yongmei Li, Lalitha Podila, Kirsten Mease, Stephen Olson, Mitchell E. Taub, Jerry O. Stern, Gerhard Nehmiz, Wulf O. Böcher, Tarik Asselah & Donald Tweedie. (2014) Mechanisms Underlying Benign and Reversible Unconjugated Hyperbilirubinemia Observed with Faldaprevir Administration in Hepatitis C Virus Patients. Journal of Pharmacology and Experimental Therapeutics 351:2, pages 403-412.
Crossref
Crossref
John Powell, Taleah Farasyn, Kathleen Köck, Xiaojie Meng, Sonia Pahwa, Kim L. R. Brouwer & Wei Yue. (2014) Novel Mechanism of Impaired Function of Organic Anion-Transporting Polypeptide 1B3 in Human Hepatocytes: Post-Translational Regulation of OATP1B3 by Protein Kinase C Activation. Drug Metabolism and Disposition 42:11, pages 1964-1970.
Crossref
Crossref
Karolin Hijazi, Constandinos Carserides & Charles Kelly. 2014. Drug Delivery and Development of Anti-HIV Microbicides. Drug Delivery and Development of Anti-HIV Microbicides
91
115
.
Thomas N. Kakuda, Anne Brochot, Frank L. Tomaka, Tony Vangeneugden, Tom Van De Casteele & Richard M. W. Hoetelmans. (2014) Pharmacokinetics and pharmacodynamics of boosted once-daily darunavir. Journal of Antimicrobial Chemotherapy 69:10, pages 2591-2605.
Crossref
Crossref
Bradley Croy Doak, Bjӧrn Over, Fabrizio Giordanetto & Jan Kihlberg. (2014) Oral Druggable Space beyond the Rule of 5: Insights from Drugs and Clinical Candidates. Chemistry & Biology 21:9, pages 1115-1142.
Crossref
Crossref
Sue‐Chih Lee, Lei Zhang & Shiew‐Mei Huang. 2014. Drug Transporters. Drug Transporters
473
490
.
Alexander Treiber, Päivi Äänismaa, Ruben de Kanter, Stephane Delahaye, Marianne Treher, Patrick Hess & Patricia Sidharta. (2014) Macitentan Does Not Interfere with Hepatic Bile Salt Transport. Journal of Pharmacology and Experimental Therapeutics 350:1, pages 130-143.
Crossref
Crossref
Joseph M. Custodio, Hui Wang, Jia Hao, Eve-Irene Lepist, Adrian S. Ray, Jessica Andrews, Kah Hiing J. Ling, Andrew Cheng, Brian P Kearney & Srinivasan Ramanathan. (2014) Pharmacokinetics of cobicistat boosted-elvitegravir administered in combination with rosuvastatin. The Journal of Clinical Pharmacology 54:6, pages 649-656.
Crossref
Crossref
Manoli Vourvahis, Anna Plotka, Constantino Kantaridis, Annie Fang & Jayvant Heera. (2014) The Effects of Boceprevir and Telaprevir on the Pharmacokinetics of Maraviroc. JAIDS Journal of Acquired Immune Deficiency Syndromes 65:5, pages 564-570.
Crossref
Crossref
Matthew L. Rizk, Robert Houle, Grace Hoyee Chan, Mike Hafey, Elizabeth G. Rhee & Xiaoyan Chu. (2014)
Raltegravir Has a Low Propensity To Cause Clinical Drug Interactions through Inhibition of Major Drug Transporters: an
In Vitro
Evaluation
. Antimicrobial Agents and Chemotherapy 58:3, pages 1294-1301.
Crossref
Crossref
Roberto Lozano, Nieves Domeque & Alberto-Fermín Apesteguia. (2014) Extended mathematical model for “in vivo” quantification of the interaction betweeen atazanavir and bilirubin. The Journal of Clinical Pharmacology 54:2, pages 161-167.
Crossref
Crossref
Shannon Dallas, Michelle L Block, Deborah M Thompson, Marcelo G Bonini, Patrick T Ronaldson, Reina Bendayan & David S Miller. (2013) Microglial activation decreases retention of the protease inhibitor saquinavir: implications for HIV treatment. Journal of Neuroinflammation 10:1.
Crossref
Crossref
Jason Zastre, Chris Dowd, James Bruckner & Andrew Popovici. (2013) Lack of P-Glycoprotein-Mediated Efflux and the Potential Involvement of an Influx Transport Process Contributing to the Intestinal Uptake of Deltamethrin, cis-Permethrin, and trans-Permethrin. Toxicological Sciences 136:2, pages 284-293.
Crossref
Crossref
Nathan D. Pfeifer, Kevin B. Harris, Grace Zhixia Yan & Kim L. R. Brouwer. (2013) Determination of Intracellular Unbound Concentrations and Subcellular Localization of Drugs in Rat Sandwich-Cultured Hepatocytes Compared with Liver Tissue. Drug Metabolism and Disposition 41:11, pages 1949-1956.
Crossref
Crossref
Yoshihisa Shitara, Kumiko Takeuchi & Toshiharu Horie. (2013) Long-Lasting Inhibitory Effects of Saquinavir and Ritonavir on OATP1B1-Mediated Uptake. Journal of Pharmaceutical Sciences 102:9, pages 3427-3435.
Crossref
Crossref
Jae H. Chang, Emile Plise, Jonathan Cheong, Quynh Ho & Molly Lin. (2013)
Evaluating the
In Vitro
Inhibition of UGT1A1, OATP1B1, OATP1B3, MRP2, and BSEP in Predicting Drug-Induced Hyperbilirubinemia
. Molecular Pharmaceutics 10:8, pages 3067-3075.
Crossref
Crossref
Tom De Bruyn, Gerard J. P. van Westen, Adriaan P. IJzerman, Bruno Stieger, Peter de Witte, Patrick F. Augustijns & Pieter P. Annaert. (2013) Structure-Based Identification of OATP1B1/3 Inhibitors. Molecular Pharmacology 83:6, pages 1257-1267.
Crossref
Crossref
Ichiro Ieiri, Shyohei Tsunemitsu, Kazuya Maeda, Yukie Ando, Noritomo Izumi, Miyuki Kimura, Naoe Yamane, Tsuyoshi Okuzono, Mariko Morishita, Naoki Kotani, Eri Kanda, Mariko Deguchi, Kyoko Matsuguma, Shunji Matsuki, Takeshi Hirota, Shin Irie, Hiroyuki Kusuhara & Yuichi Sugiyama. (2013) Mechanisms of Pharmacokinetic Enhancement Between Ritonavir and Saquinavir; Micro/Small Dosing Tests Using Midazolam (CYP3A4), Fexofenadine (p‐Glycoprotein), and Pravastatin (OATP1B1) as Probe Drugs. The Journal of Clinical Pharmacology 53:6, pages 654-661.
Crossref
Crossref
Dinko Rekić, Daniel Röshammar, Martin Bergstrand, Joel Tarning, Andrea Calcagno, Antonio D’Avolio, Vidar Ormaasen, Marie Vigan, Aurélie Barrail-Tran, Michael Ashton, Magnus Gisslén & Angela Äbelö. (2012) External Validation of the Bilirubin–Atazanavir Nomogram for Assessment of Atazanavir Plasma Exposure in HIV-1-Infected Patients. The AAPS Journal 15:2, pages 308-315.
Crossref
Crossref
Olena Kis, Jason A. Zastre, Md. Tozammel Hoque, Sharon L. Walmsley & Reina Bendayan. (2012) Role of Drug Efflux and Uptake Transporters in Atazanavir Intestinal Permeability and Drug-Drug Interactions. Pharmaceutical Research 30:4, pages 1050-1064.
Crossref
Crossref
Li Liu & Jashvant D. Unadkat. (2013) Interaction between HIV protease inhibitors (PIs) and hepatic transporters in sandwich cultured human hepatocytes: implication for PI‐based DDIs. Biopharmaceutics & Drug Disposition 34:3, pages 155-164.
Crossref
Crossref
Ellen G. J. Hulskotte, Hwa-Ping Feng, Fengjuan Xuan, Marga G. J. A. van Zutven, Michelle A. Treitel, Eric A. Hughes, Edward O'Mara, Stephen P. Youngberg, John A. Wagner & Joan R. Butterton. (2013) Pharmacokinetic Interactions Between the Hepatitis C Virus Protease Inhibitor Boceprevir and Ritonavir-Boosted HIV-1 Protease Inhibitors Atazanavir, Darunavir, and Lopinavir. Clinical Infectious Diseases 56:5, pages 718-726.
Crossref
Crossref
Atsuko Tomaru, Mariko Takeda-Morishita, Hirokazu Banba & Kozo Takayama. (2013) Analysis of the Pharmacokinetic Boosting Effects of Ritonavir on Oral Bioavailability of Drugs in Mice. Drug Metabolism and Pharmacokinetics 28:2, pages 144-152.
Crossref
Crossref
Yurong Lai. 2013. Transporters in Drug Discovery and Development. Transporters in Drug Discovery and Development
353
454
.
ND Pfeifer, SL Goss, B Swift, G Ghibellini, M Ivanovic, WD Heizer, LM Gangarosa & KLR Brouwer. (2013)
Effect of Ritonavir on
99m
Technetium–Mebrofenin Disposition in Humans: A Semi‐PBPK Modeling and
In Vitro
Approach to Predict Transporter‐Mediated DDIs
. CPT: Pharmacometrics & Systems Pharmacology 2:1, pages 1-10.
Crossref
Crossref
Per Artursson, Pär Matsson & Maria Karlgren. 2013. Transporters in Drug Development. Transporters in Drug Development
37
65
.
Lei Zhang & Shiew-Mei Huang. 2013. Transporters in Drug Development. Transporters in Drug Development
257
283
.
Christina L. Aquilante, Jennifer J. Kiser, Peter L. Anderson, Uwe Christians, Lisa A. Kosmiski, Elizabeth B. Daily, Keith L. Hoffman, Charles W. Hopley, Julie A. Predhomme, Bjorn Schniedewind & Maha S. Sidhom. (2013)
Influence of
SLCO1B1
Polymorphisms on the Drug‐Drug Interaction Between Darunavir/Ritonavir and Pravastatin
. The Journal of Clinical Pharmacology 52:11, pages 1725-1738.
Crossref
Crossref
Anne Sophie Grandvuinet, Henrik Tang Vestergaard, Nicolas Rapin & Bente Steffansen. (2012) Intestinal transporters for endogenic and pharmaceutical organic anions: the challenges of deriving in-vitro kinetic parameters for the prediction of clinically relevant drug–drug interactions. Journal of Pharmacy and Pharmacology 64:11, pages 1523-1548.
Crossref
Crossref
Annett Kunze, Jörg Huwyler, Gian Camenisch & Heike Gutmann. (2012) Interaction of the antiviral drug telaprevir with renal and hepatic drug transporters. Biochemical Pharmacology 84:8, pages 1096-1102.
Crossref
Crossref
Manthena V. S. Varma, Yurong Lai, Bo Feng, John Litchfield, Theunis C. Goosen & Arthur Bergman. (2012) Physiologically Based Modeling of Pravastatin Transporter-Mediated Hepatobiliary Disposition and Drug-Drug Interactions. Pharmaceutical Research 29:10, pages 2860-2873.
Crossref
Crossref
Micaela B. Reddy, Yuan Chen, Joshua Ö. Haznedar, Jennifer Fretland, Steven Blotner, Patrick Smith & Jonathan Q. Tran. (2012) Impact of Low-Dose Ritonavir on Danoprevir Pharmacokinetics. Clinical Pharmacokinetics 51:7, pages 457-465.
Crossref
Crossref
Veronique Michaud, Tamara Bar-Magen, Jacques Turgeon, David Flockhart, Zeruesenay Desta & Mark A. Wainberg. (2012) The Dual Role of Pharmacogenetics in HIV Treatment: Mutations and Polymorphisms Regulating Antiretroviral Drug Resistance and Disposition. Pharmacological Reviews 64:3, pages 803-833.
Crossref
Crossref
Divya Samineni, Pankaj B. Desai, Larry Sallans & Carl J. Fichtenbaum. (2013) Steady‐State Pharmacokinetic Interactions of Darunavir/Ritonavir With Lipid‐Lowering Agent Rosuvastatin. The Journal of Clinical Pharmacology 52:6, pages 922-931.
Crossref
Crossref
Li Liu, Ganesh M. Mugundu, Brian J. Kirby, Divya Samineni, Pankaj B. Desai & Jashvant D. Unadkat. (2012) Quantification of human hepatocyte cytochrome P450 enzymes and transporters induced by HIV protease inhibitors using newly validated LC-MS/MS cocktail assays and RT-PCR. Biopharmaceutics & Drug Disposition 33:4, pages 207-217.
Crossref
Crossref
Megan Roth, Amanda Obaidat & Bruno Hagenbuch. (2012) OATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamilies. British Journal of Pharmacology 165:5, pages 1260-1287.
Crossref
Crossref
S-M Huang & M Rowland. (2012) The Role of Physiologically Based Pharmacokinetic Modeling in Regulatory Review. Clinical Pharmacology & Therapeutics 91:3, pages 542-549.
Crossref
Crossref
Donna A Volpe. (2011) Drug-permeability and transporter assays in Caco-2 and MDCK cell lines. Future Medicinal Chemistry 3:16, pages 2063-2077.
Crossref
Crossref
Dinko Rekić, Oskar Clewe, Daniel Röshammar, Leo Flamholc, Anders Sönnerborg, Vidar Ormaasen, Magnus Gisslén, Angela Äbelö & Michael Ashton. (2011) Bilirubin—A Potential Marker of Drug Exposure in Atazanavir-Based Antiretroviral Therapy. The AAPS Journal 13:4, pages 598-605.
Crossref
Crossref
Gerard Minuesa, Isabel Huber-Ruano, Marçal Pastor-Anglada, Hermann Koepsell, Bonaventura Clotet & Javier Martinez-Picado. (2011) Drug uptake transporters in antiretroviral therapy. Pharmacology & Therapeutics 132:3, pages 268-279.
Crossref
Crossref
Hyo-Kyung Han. (2011) Role of transporters in drug interactions. Archives of Pharmacal Research 34:11, pages 1865-1877.
Crossref
Crossref
Tom De Bruyn, Sarinj Fattah, Bruno Stieger, Patrick Augustijns & Pieter Annaert. (2011) Sodium fluorescein is a probe substrate for hepatic drug transport mediated by OATP1B1 and OATP1B3. Journal of Pharmaceutical Sciences 100:11, pages 5018-5030.
Crossref
Crossref
Ana Catalán-Latorre, Amparo Nácher, Virginia Merino, Nicolás Víctor Jiménez-Torres & Matilde Merino-Sanjuán. (2011) In Situ Study of the Effect of Naringin, Talinolol and Protein-Energy Undernutrition on Intestinal Absorption of Saquinavir in Rats. Basic & Clinical Pharmacology & Toxicology 109:4, pages 245-252.
Crossref
Crossref
Latoya Griffin, Pieter Annaert & Kim L.R. Brouwer. (2011) Influence of Drug Transport Proteins on the Pharmacokinetics and Drug Interactions of Hiv Protease Inhibitors. Journal of Pharmaceutical Sciences 100:9, pages 3636-3654.
Crossref
Crossref
Fabian MüllerMartin F Fromm. (2011) Transporter-mediated drug–drug interactions. Pharmacogenomics 12:7, pages 1017-1037.
Crossref
Crossref
John W. Murray, Amar J. Thosani, Pijun Wang & Allan W. Wolkoff. (2011) Heterogeneous accumulation of fluorescent bile acids in primary rat hepatocytes does not correlate with their homogenous expression of ntcp. American Journal of Physiology-Gastrointestinal and Liver Physiology 301:1, pages G60-G68.
Crossref
Crossref
David A. Brealey, Mervyn Singer & Marius Terblanche. (2011) Potential metabolic consequences of statins in sepsis*. Critical Care Medicine 39:6, pages 1514-1520.
Crossref
Crossref
Mikko Niemi, Marja K. Pasanen & Pertti J. Neuvonen. (2011) Organic Anion Transporting Polypeptide 1B1: a Genetically Polymorphic Transporter of Major Importance for Hepatic Drug Uptake. Pharmacological Reviews 63:1, pages 157-181.
Crossref
Crossref
P. Martinez-Becerra, O. Briz, M. R. Romero, R. I. R. Macias, M. J. Perez, C. Sancho-Mateo, M. P. Lostao, J. M. Fernandez-Abalos & J. J. G. Marin. (2010) Further Characterization of the Electrogenicity and pH Sensitivity of the Human Organic Anion-Transporting Polypeptides OATP1B1 and OATP1B3. Molecular Pharmacology 79:3, pages 596-607.
Crossref
Crossref
Catia Marzolini, Manuel Battegay & David Back. 2011. Drug Interactions in Infectious Diseases. Drug Interactions in Infectious Diseases
43
72
.
F. Josephson. (2010) Drug–drug interactions in the treatment of HIV infection: focus on pharmacokinetic enhancement through CYP3A inhibition. Journal of Internal Medicine 268:6, pages 530-539.
Crossref
Crossref
Olena Kis, Jason A. Zastre, Manisha Ramaswamy & Reina Bendayan. (2010) pH Dependence of Organic Anion-Transporting Polypeptide 2B1 in Caco-2 Cells: Potential Role in Antiretroviral Drug Oral Bioavailability and Drug–Drug Interactions. Journal of Pharmacology and Experimental Therapeutics 334:3, pages 1009-1022.
Crossref
Crossref